Saturday, 15 December 2018 14:05

Anticoagulation news items. Week commencing 10th December 2018

In use product safety assessment report for enoxaparin biosimilars (INHIXA and AROVI)

Specialist Pharmacy Service

This assessment on Inhixa and Arovi (enoxaparin biosimilars) describes the in-use medication safety considerations resultant from the products' presentation or other pre-defined characteristics. Potential next steps and mitigation actions are suggested.

 

Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism

JAMA Oncology

An overview of the evidence that this drug class (of which palbociclib is the first in class) is associated with an increased incidence of thromboembolism. NICE support the use of palbociclib for use within its marketing authorisation.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services